@article{CCO31331,
author = {Carlo Visco and Francesca Maria Quaglia and Chiara Bovo and Maria Chiara Tisi and Mauro Krampera},
title = {Bendamustine plus rituximab: is it a BRIGHT idea?},
journal = {Chinese Clinical Oncology},
volume = {9},
number = {2},
year = {2019},
keywords = {},
abstract = {Flinn et al. have reported the results of the long-term follow-up for the BRIGHT trial, an international study which compared the efficacy and the safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma (iNHL) or mantle-cell lymphoma (MCL).},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/31331}
}